%0 Journal Article
%T Novel Therapies for the Treatment of Cardiovascular Disease.
%A Asbeutah AAA
%A Goldberger ZD
%J Med Clin North Am
%V 108
%N 5
%D 2024 Sep
%M 39084843
%F 6.912
%R 10.1016/j.mcna.2024.03.003
%X Over the last decade, randomized clinical trials of several pharmacologic agents have demonstrated a reduction in cardiovascular mortality and other important secondary outcomes. Angiotensin-Neprilysin Inhibitors and Sodium-Glucose Co-transporter 2 inhibitors have now become pillars in the treatment of heart failure. Ivabradine is a negative chronotropic agent used as an adjunctive therapy in patients with heart failure. Two new hypertension therapies, zilebresiran and aprocitentan, are currently in investigational stages. Finally, mavacamten has emerged as a pharmacologic treatment for hypertrophic obstructive cardiomyopathy. Practitioners must be familiar with the indications and side effects of newer therapies as they are now frequently prescribed.